Acne Vulgaris

Last updated: March 9, 2026
Table Of Contents

Overview

Acne vulgaris (aka ‘acne’) is a very common disorder of the pilosebaceous follicles (oil glands). It results from excess production of sebum, which is related to androgen (testosterone) levels. It is associated with psychological distress (including depression, anxiety, and social phobia). Early treatment leads to better outcomes and reduces the risk of long-term scarring. The diagnosis is clinical. It is important to remember that acne can be disfiguring, has a large psychological impact, and has the potential for (avoidable) scarring. Cystic acne should be referred to a specialist (dermatologist) to reduce the risk of scarring.

Acne peaks in teenage years (second decade) and may continue into adulthood, where it affects 15% of women and 5% of men.

Lesions seen in acne

LesionDescription
Obstructed pilosebaceous units. Can cause scarring and lead to cysts.Indicates hyperkeratinisation. Does not form cysts.
Closed comedones (whiteheads)Small, inflammatory, and usually raised, red lesions
Papules (deep)Fills up within the months after a flare-up. Scarring is fully assessed once the inflammatory phase has resolved.
PustulesMore superficial than papules
NodulesBigger papules
Cysts> 5mm in size. Develops when there is further infection and inflammation by P. acnes. Can be treated with intra-lesion steroids, antibiotics, and isotretinoin
Atrophic scarsFills up within the months after flare-up. Scarring is fully assessed once the inflammatory phase has resolved.

Acne according to severity

SeverityFeatures
Mild acneOpen and closed comedones with minimal inflammatory lesions
Moderate acneWidespread non-inflammatory lesions with many papules and pustules
Severe acneExtensive inflammatory lesionsl including nodules, pitting, and scarring
  • Causes of acne
    • Androgenic stimulation of the sebaceous gland (increased sensitivity to androgens)
    • Polycystic Ovarian Syndrome (PCOS)
    • Steroid Use
    • Skincare products that increase oil load on the skin e.g. heavy make-up
    • Full-fat milk has a slight effect on the development, but there is no clear relation between acne and diet
  • Pathophysiology
    • Increased sebum production: Sebum production is driven by an increase in androgens. Increased sebum favours the proliferation of skin microorganisms and follicular occlusion.
    • Follicular hyperkeratinisation: keratinocytes proliferate and differentiate abnormally within the pilosebaceous unit. This forms a keratinous plug known as a microcomedo (the lesion)
    • Colonisation with Propionibacterium acnes: anaerobic bacteria like P. acnes overgrow in the follicle due to increased sebum. They metabolize triglycerides into fatty acids, which attract neutrophils and monocytes.
    • Inflammation: the immune system responds to P. acnes by releasing pro-inflammatory cytokines. This leads to inflammation, erythema, and inflammatory lesions (papules, pustules, nodules, and cysts)
  • Areas affected by acne
    • The face (universal)
    • Chest, neck, and back (severe cases)
  • Signs and symptoms
    • Non-inflammatory lesions (mild acne) – open and closed comedones
    • Inflammatory lesions (moderate and severe acne) – papules, pustules, nodules, and cysts
  • Features of severe acne
    • A large number of comedones
    • Scarring
    • Resistant to basic treatment
    • Affects the trunk
    • Has a large psychological impact
  • Differentials
  • Indications for early referral to a dermatologist (specialist) and isotretinoin treatment
    • Concern for severe acne
    • Strong family history
    • Signs of scarring
    • Rapid progression
  • Complications of acne
    • Post-inflammatory hyperpigmentation (in darker skin types)
    • Post-inflamatory erythema (in lighter skin types)
    • Scarring
    • Nodulocystic lesions
    • Secondary infection
    • Psychological and social effects, e.g. Depression, Anxiety, social withdrawal, and suicidal ideation
    • Antibiotic resistance
    • Tetracycline teeth staining
    • Side effects of isotretinoin (teratogenicity, hyperlipidaemia, and hepatotoxicity)

Treatment of Acne

Treatment needs to be continued for at least 6 weeks to produce effects. Topical therapies are used for mild acne, oral therapies for moderate-severe acne, and oral retinoids for severe acne

Principles of treating acne

PrincipleTreatment
Comedolysis (unblock pores)Topical benzoyl peroxide, isotretinoin gel, adapalene lotion
Decrease bacterial load in sebumTopical or oral antibiotics
Decrease sebaceous gland activityIsotretinoin (oral), Combined Oral Contraceptives (women only), Spironolactone (women only)

Treatment according to severity

SeverityTreatment
Mild acneTopical combination agents
Moderate-to severe acneTopical or systemic (oral) combination agents
Severe acneSystemic (oral) combination agents
  • Conservative management of acne
    • Reassurance that acne is often mild and self-limiting
    • Wash twice daily with soap and water
    • Avoid the use of oily skin products (use cosmetics sparingly)
    • Advice that sunlight can increase the risk of scarring/make the scars appear more visible
  • Topical combination agents for treating acne
    • Benzoyl peroxide (first line)
    • Topical antibiotics (clindamycin and erythromycin) + benzoyl peroxide to reduce resistance
    • Topical retinoids (adapeline) +/- benzoyl peroxide
  • Systemic treatment of acne
    • Oral antibiotics
      • Tetracycline (doxycycline, minocycline, lymecycline) is the first-line oral antibiotic
      • Clindamycin and erythromycin can be used in pregnancy
    • Isotretinoin: prescribed by a dermatologist, very effective and teratogenic, contraindicated while using tetracycline (risk of benign intracranial hypertension), and with progesterone only pill (reduces effectiveness and increases the risk of pregnancy)
    • Antiandrogens
      • Oral Contraceptive Pills, e.g., Dianette (co-cyprindiol), can be used in place of oral antibiotics in women
      • Spironolactone (used off-label)
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *